Literature DB >> 24825333

Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis.

Bronwyn J Silver1, Rebecca J Guy, John M Kaldor, Muhammad S Jamil, Alice R Rumbold.   

Abstract

Trichomonas vaginalis is the most common curable sexually transmissible infection worldwide, with high rates in women of reproductive age. There have been inconsistent findings about the impact of infection and its treatment in pregnancy. We conducted a meta-analysis to determine the association between T. vaginalis and perinatal outcomes. Electronic databases were searched to May 2013. Included studies reported perinatal outcomes in women infected and uninfected with T. vaginalis. Meta-analysis calculated a pooled relative risk (RR) and 95% confidence interval (CI) using either a fixed- or random-effects model. Study bias was assessed using funnel plots. Of 178 articles identified, 11 studies met the inclusion criteria. The study populations, outcomes, and quality varied. T. vaginalis in pregnancy was associated with an increased risk of preterm birth (RR, 1.42; 95% CI, 1.15-1.75; 9 studies; n = 81,101; I = 62.7%), preterm premature rupture of membranes (RR, 1.41; 95% CI,1.10-1.82; 2 studies; n = 14,843; I = 0.0%) and small for gestational age infants (RR, 1.51; 95% CI,1.32-1.73; 2 studies; n = 14,843; I = 0.0%). Sensitivity analyses of studies that accounted for coinfection with other sexually transmissible infection found a slightly reduced RR of 1.34 for preterm birth (95% CI, 1.19-1.51; 6 studies; n = 72,077; I = 11.2%), and in studies where no treatment was confirmed, the RR was 1.83 (95% CI, 0.98-3.41; 3 studies; n = 1795; I = 22.3%). Our review provides strong evidence that T. vaginalis in pregnancy is associated with an increased risk of preterm birth. Based on fewer studies, there were also substantial increases in the risk of preterm premature rupture of membranes and small for gestational age infants. Further studies that address the current gaps in evidence on treatment effects in pregnancy are needed.

Entities:  

Mesh:

Year:  2014        PMID: 24825333     DOI: 10.1097/OLQ.0000000000000134

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  78 in total

Review 1.  Mycoplasma genitalium and Trichomonas vaginalis: addressing disparities and promoting public health control of two emerging sexually transmitted infections.

Authors:  Faye Korich; Neha G Reddy; Maria Trent
Journal:  Curr Opin Pediatr       Date:  2020-08       Impact factor: 2.856

2.  Trichomonas vaginalis and Human Immunodeficiency Virus Coinfection Among Women Under Community Supervision: A Call for Expanded T. vaginalis Screening.

Authors:  Alissa Davis; Anindita Dasgupta; Dawn Goddard-Eckrich; Nabila El-Bassel
Journal:  Sex Transm Dis       Date:  2016-10       Impact factor: 2.830

3.  Clinical performance of the Solana® Point-of-Care Trichomonas Assay from clinician-collected vaginal swabs and urine specimens from symptomatic and asymptomatic women.

Authors:  C A Gaydos; J Schwebke; J Dombrowski; J Marrazzo; J Coleman; B Silver; M Barnes; L Crane; P Fine
Journal:  Expert Rev Mol Diagn       Date:  2017-01-29       Impact factor: 5.225

Review 4.  Prevalence of Curable Sexually Transmitted Infections in Pregnant Women in Low- and Middle-Income Countries From 2010 to 2015: A Systematic Review.

Authors:  D L Joseph Davey; H I Shull; J D Billings; D Wang; K Adachi; J D Klausner
Journal:  Sex Transm Dis       Date:  2016-07       Impact factor: 2.830

5.  Anti-Trichomonas vaginalis activity of ursolic acid derivative: a promising alternative.

Authors:  Fernanda Gobbi Bitencourt; Patrícia de Brum Vieira; Lucia Collares Meirelles; Graziela Vargas Rigo; Elenilson Figueiredo da Silva; Simone Cristina Baggio Gnoatto; Tiana Tasca
Journal:  Parasitol Res       Date:  2018-03-23       Impact factor: 2.289

6.  Combined Testing for Chlamydia, Gonorrhea, and Trichomonas by Use of the BD Max CT/GC/TV Assay with Genitourinary Specimen Types.

Authors:  Barbara Van Der Pol; James A Williams; DeAnna Fuller; Stephanie N Taylor; Edward W Hook
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

7.  Epidemiology and treatment of trichomoniasis.

Authors:  Patricia Kissinger
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

8.  Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing.

Authors:  Megan Clare Craig-Kuhn; Charleigh Granade; Christina A Muzny; Barbara Van Der Pol; Rebecca Lillis; Stephanie N Taylor; Norine Schmidt; David H Martin; Patricia Kissinger
Journal:  Sex Transm Dis       Date:  2019-05       Impact factor: 2.830

9.  Prevalence and Correlates of Trichomonas vaginalis Infection Among Men and Women in the United States.

Authors:  Eshan U Patel; Charlotte A Gaydos; Zoe R Packman; Thomas C Quinn; Aaron A R Tobian
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

10.  Rapid Diagnosis of Trichomonas vaginalis by Testing Vaginal Swabs in an Isothermal Helicase-Dependent AmpliVue Assay.

Authors:  Charlotte A Gaydos; Marcia Hobbs; Jeanne Marrazzo; Jane Schwebke; Jenell S Coleman; Billie Masek; Laura Dize; Dan Jang; Jenny Li; Max Chernesky
Journal:  Sex Transm Dis       Date:  2016-06       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.